Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by AUAUniversity and American Urological Association. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by AUAUniversity and American Urological Association or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

The Latest Breakthroughs in mHSPC

1:14:39
 
Share
 

Manage episode 508155667 series 2497848
Content provided by AUAUniversity and American Urological Association. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by AUAUniversity and American Urological Association or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
The Latest Breakthroughs in mHSPC CME Available: https://auau.auanet.org/node/43825 After participating in this CME activity, participants will be able to: 1.Evaluate the concept of personalized therapy and its importance in the treatment of de novo mHSPC. 2.Implement current clinical guidelines for biomarker testing in mHSPC. 3.Explain the role of the PI3K/AKT pathway in prostate cancer biology. 4.Explore collaborations between urologists, oncologists, radiologists, and other healthcare professionals in managing de novo mHSPC. 5.Employ strategies to manage and mitigate common adverse events associated with AKT inhibitors and other therapies used in mHSPC. Acknowledgements: AstraZeneca Bayer HealthCare Pharmaceuticals Inc.
  continue reading

406 episodes

Artwork

The Latest Breakthroughs in mHSPC

AUAUniversity

21 subscribers

published

iconShare
 
Manage episode 508155667 series 2497848
Content provided by AUAUniversity and American Urological Association. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by AUAUniversity and American Urological Association or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
The Latest Breakthroughs in mHSPC CME Available: https://auau.auanet.org/node/43825 After participating in this CME activity, participants will be able to: 1.Evaluate the concept of personalized therapy and its importance in the treatment of de novo mHSPC. 2.Implement current clinical guidelines for biomarker testing in mHSPC. 3.Explain the role of the PI3K/AKT pathway in prostate cancer biology. 4.Explore collaborations between urologists, oncologists, radiologists, and other healthcare professionals in managing de novo mHSPC. 5.Employ strategies to manage and mitigate common adverse events associated with AKT inhibitors and other therapies used in mHSPC. Acknowledgements: AstraZeneca Bayer HealthCare Pharmaceuticals Inc.
  continue reading

406 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play